0000899243-23-012119.txt : 20230503 0000899243-23-012119.hdr.sgml : 20230503 20230503173944 ACCESSION NUMBER: 0000899243-23-012119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230501 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 23885586 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER NAME: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-01 0 0001840229 MiNK Therapeutics, Inc. INKT 0001098972 AGENUS INC 3 FORBES ROAD LEXINGTON MA 02421 0 0 1 0 0 Common Stock 2023-05-01 4 J 0 4988273 0.00 D 21344685 D On May 1, 2023, Agenus Inc. ("Agenus") paid its previously announced pro rata stock dividend (the "Dividend") consisting of an aggregate of 4,988,081 shares of common stock of MiNK Therapeutics, Inc. ("MiNK") held by Agenus (the "Dividend Shares") to record holders of Agenus's common stock as of April 17, 2023 (the "Record Date"). Agenus distributed 0.0146 of a share of MiNK's common stock for each share of Agenus's common stock outstanding as of the close of business on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of Agenus who were entitled to receive fractional shares of the Dividend Shares received cash (without interest) in lieu of such fractional shares and 192 MiNK shares owned by Agenus that represented the aggregate number of fractional shares that would have been distributed were retired. /s/ Christine Klaskin, Vice President, Finance 2023-05-03